bendamustine hydrochloride
bendamustine hydrochloride is listed in the FDA National Drug Code directory with 8 NDC codes, marketed under brand names including Bendeka, BENDAMUSTINE HYDROCHLORIDE, bendamustine hydrochloride. Available dosage forms: injection, solution, injection, injection, powder, lyophilized, for solution, powder.
Drug details
- Generic Name
- bendamustine hydrochloride
- Brand Names
- Bendeka, BENDAMUSTINE HYDROCHLORIDE, bendamustine hydrochloride, BELRAPZO
- Application Number
- NDA208194
- Sponsor
- Teva Pharmaceuticals USA, Inc.
- NDC Codes
- 8
- Dosage Forms
- INJECTION, SOLUTION, INJECTION, INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION, POWDER
- Routes
- INTRAVENOUS
- Active Ingredients
- BENDAMUSTINE HYDROCHLORIDE
Indications and Usage
1 INDICATIONS AND USAGE Non-Hodgkin Lymphoma (NHL) Bendamustine hydrochloride injection is indicated for the treatment of adult patients with indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine hydrochloride injection is an alkylating drug indicated for treatment of adult patients with: • Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. ( 1 )